Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...

The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...

Astellas Pharma Inc. rose the most in more than three months after quarterly profit exceeded analysts’ projections, driven by robust sales of its Padcev cancer treatment and Mirabegron used to control ...

US pharma giant Pfizer and Japan’s Astellas Pharma today announced positive top-line results from the Phase III EV-303 ...

The combination of Padcev and Keytruda delivered a phase 3 win in muscle-invasive bladder cancer. China did not renew the conditional approval for a controversial Alzheimer's disease drug. | The ...

Pfizer (NYSE:PFE) and Astellas Pharma (OTCPK:ALPMF) announced on Tuesday that their jointly developed antibody-drug conjugate ...

An announcement from Astellas Pharma ( ($JP:4503) ) is now available. Pfizer and Astellas Pharma have announced positive results from their Phase ...

Can Boston stay on top in biotech? Find out on Sept 17, 6-9 p.m. EDT to explore talent shifts, funding, and Boston’s future.

Astellas has reached Phase 1 testing with ASP3082, an internally developed drug candidate designed to degrade a cancer target called KRAS G12D. Mutated versions of this protein are found in ...

Photo: Akio Kon/Bloomberg News Astellas Pharma Inc. said Monday that it agreed to acquire Iveric bio Inc. for about $5.9 billion to strengthen its capabilities in the ophthalmology field.

Astellas Pharma US Inc., the U.S. division of Tokyo-based Astellas Pharma Inc., will officially open its $150 million corporate campus Monday in Northbrook, a site that will serve as the […] ...